

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 8 JULY 2020

Reference is made to the circular of Sinopharm Tech Holdings Limited (the “**Company**”) dated 19 June 2020 (the “**Circular**”) and the notice of the extraordinary general meeting of the Company (the “**EGM**”) dated 19 June 2020 (the “**Notice**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Circular.

POLL RESULTS OF THE EGM

The Board is pleased to announce that at the EGM held on Wednesday, 8 July 2020, the proposed ordinary resolution (the “**Resolution**”) as set out in the Notice was duly passed by the Independent Shareholders by way of poll.

The poll results in respect of the Resolution proposed are as follows:

ORDINARY RESOLUTION	Number of Votes (%)	
	For	Against
To approve, confirm and ratify the Subscription Agreement and the transactions contemplated thereunder (including but not limited to the grant of the Specific Mandate to the Directors for the allotment and issue of the Subscription Shares), details of which are set out in the notice convening the Meeting.	465,808,000 (100.00%)	0 (0.00%)

As more than 50% of the votes were cast in favour of the above Resolution, this Resolution was duly passed as an ordinary resolution of the Company at the EGM.

CCTH CPA Limited, the auditors of the Company, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

As at the date of the EGM, the total issued Share capital of the Company were 4,289,724,633 Shares. The Subscriber, by virtue of his material interest in the Subscription Agreement and the transactions contemplated thereunder, and his associates, including Madam Cheung Kwai Lan, Mr. Chan Tung Mei and Best Frontier, were required under the GEM Listing Rules to abstain and had abstained from voting on the Resolution at the EGM in compliance with the GEM Listing Rules. Save as disclosed above, to the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, no other Shareholder was required to abstain from voting on the Resolution at the EGM. As at the date of this announcement, the Subscriber, Madam Cheung Kwai Lan, Mr. Chan Tung Mei and Best Frontier together controlled or was entitled to exercise control over the voting right of an aggregate of 640,596,856 Shares, representing approximately 14.93% of the total issued Shares. Accordingly, there were 3,649,127,777 Shares entitling the Independent Shareholders to attend and vote on the proposed Resolution at the EGM. There were no Independent Shareholders who were entitled to attend the EGM but were only entitled to vote against the proposed Resolution at the EGM.

By Order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Executive Director and Chief Executive Officer

Hong Kong, 8 July 2020

As at the date of this announcement, the Board comprises Madam CHEUNG Kwai Lan, Mr. CHAN Ting as executive Directors, Mr. CHAN Tung Mei and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.